Ratings by Piper Sandler (Edward A. Tenthoff)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2026 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2026 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/8/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2025 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2025 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2025 | iTeos Therapeutics | ITOS | Downgrade | Neutral (Overweight) |
10.26 (10.15) |
-1.07% | Details | |
| 5/29/2025 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2025 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2025 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/27/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2024 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/18/2024 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/6/2024 | Seres Therapeutics | MCRB | Downgrade | Neutral (Overweight) |
1.14 (9.13) |
700.88% | Details | |
| 5/24/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2024 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2024 | Aslan Pharma | ASLN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2024 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2023 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2023 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2023 | Aslan Pharma | ASLN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2023 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2023 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2022 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/23/2022 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2022 | Aeglea Biotherapeutics | AGLE | Upgrade | Overweight (Neutral) |
0.50 (12.01) |
2302% | Details | |
| 9/16/2022 | Aslan Pharma | ASLN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2022 | Seres Therapeutics | MCRB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2022 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2022 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2022 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2022 | Aeglea Biotherapeutics | AGLE | Downgrade | Neutral (Overweight) |
1.50 (12.01) |
700.67% | Details | |
| 5/23/2022 | Seres Therapeutics | MCRB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Eloxx Pharma | ELOX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Aslan Pharma | ASLN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2022 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2022 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2022 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2022 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/6/2021 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2021 | Yumanity Therapeutics Inc. | YMTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2021 | Bicycle Therapeutics | BCYC | Maintain | (N/A) |
|
Details | ||
| 9/20/2021 | Synlogic Inc. | SYBX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2021 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2021 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2021 | Seres Therapeutics | MCRB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2021 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2021 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2021 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2021 | Arrowhead Pharma | ARWR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/26/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2021 | Eloxx Pharma | ELOX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Aslan Pharma | ASLN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/15/2021 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2021 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2021 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2020 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 10/14/2020 | Proteostasis Therapeutics | PTI | Upgrade | Overweight (Neutral) |
1.19 (1.11) |
-6.72% | Details | |
| 9/21/2020 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2020 | Aptevo Therapeutics | APVO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2020 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2020 | Opko Health | OPK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2020 | Aptevo Therapeutics | APVO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2020 | Aptevo Therapeutics | APVO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2020 | Marker Therapeutics | MRKR | Downgrade | Neutral (Overweight) |
2.40 (1.38) |
-42.5% | Details | |
| 2/28/2020 | Aptevo Therapeutics | APVO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2020 | Marker Therapeutics | MRKR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/25/2019 | Eloxx Pharma | ELOX | Maintain | Overweight (Overweight) |
|
Details |
